Adam Resnick
Has grant
Director
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
Deciphering the 3D genome of pediatric brain tumors
Open Date: 2022-09-20
Close Date: 2024-09-19
Grant: Close
Deep Phenotyping Children with Congenital Anomalies and Cancer Enrolled in Project:EveryChild
Open Date: 2022-05-01
Close Date: 2025-04-30
Grant: Close
Data Management and Portal for the INCLUDE (DAPI) Project
Open Date: 2020-09-26
Close Date: 2025-08-31
Grant: Close
Kids First Data Resource Center (KFDRC): Harnessing Data-Driven Opportunities in the Present on behalf of the Future of Common Fund Data Ecosystem (CFDE)
Open Date: 2020-09-25
Close Date: 2024-09-24
Grant: Close
Functional characterization and drug targeting of MET gene fusions in DMGs
Open Date: 2020-07-01
Close Date: 2022-02-28
Articles (18)
Background/Objectives: Prostate-specific membrane antigen (PSMA) is a well-established target in prostate cancer therapy that has shown potential as a theranostic target across non-central nervous system (CNS) and CNS tumor types. We aimed to investigate the pan-tissue expression pattern of the PSMA-encoding gene FOLH1 to assess whether transcriptome profiling can inform tumor diagnostic and theranostic probes. Methods: We assessed FOLH1 expression from the Open Pediatric Cancer Project (OpenPedCan, n = 2132 specimens), the Cancer Genome Atlas (TCGA, n = 10,411 specimens), and the Genotype Tissue Expression Project (GTEx, n = 17,382 specimens) in relation to published reports of PSMA radionuclide uptake in various tumors. Results: When comparing FOLH1 expression across tumor versus normal tissues, we found that non-CNS tumors exhibiting elevated expression of at least two-fold (FDR < 0.05) were reported to have significant PSMA radionuclide uptake in contrast to tumors with less than a two-fold elevation or with lower expression of FOLH1 relative to normal tissues. Notably, CNS tumors universally exhibited lower expression of FOLH1 relative to normal brain tissue, but we observed considerable variation in the expression of blood–tumor barrier (BTB) components associated with reports of BTB integrity and uptake of PSMA radiotracers. Conclusions: Large-scale transcriptomics data may help guide the application of PSMA-based radionuclide therapies in non-CNS tumors, but care should be taken to account for BTB effects in CNS tumors when assessing the potential for radionuclide success. This study demonstrates that FOLH1 showed a lack of tumor-specific expression for both adult and pediatric CNS tumors when compared to normal brain tissue, suggesting that PSMA is not a desirable target in brain tumors.
Year:
2025
Contains supplementary data and table titles and as well as supplementary figures with associated titles and legends.Fig. S1. Selection method for planned efficacy analysis of ONC201 in patients with H3K27MDMG.Fig. S2. Progression-free survival from diagnosis of trial patients with non-recurrent H3K27MDMG treated with ONC201.Fig. S3. Swimmers’ plot of ONC201 response by recurrence status, tumor location, and ONC201 trial.Fig. S4. ONC201 efficacy is independent of TP53 mutation status and chromosomal instability.Fig. S5. Cox proportional hazard regression to assess the effect of ONC201 after adjusting for confounders.Fig. S6. Survival of patients with H3K27M-DMG treated with ONC201 versus ONC201untreated historical controls.Fig. S7. Survival of patients with H3K27M-DMG treated with ONC201 versus ONC201untreated patients (PNOC003 or HERBY Phase II trials).Fig. S8. Molecular attributes of patients with H3K27M-DMG treated with ONC201.Fig. S9: Survival of H3K27M-DMG mice models treated with ONC201.Fig. S10. Integrative analysis of in vitro and human tumor metabolic gene expression in response to ONC201.Fig. S11. ONC201-mediated L2HG production increases H3K27me3 in H3K27M-DMG cells.Fig. S12. ONC201-induced increase in H3K27me3 is mediated by lactate dehydrogenase.Fig. S13. ONC201 alters genomic chromatin accessibility and H3K27ac distribution in H3K27M-DMG cells.Fig. S14. ONC201 increases global H3K27me3 in patient samples.Fig. S15. ONC201 does not cause hypermethylation leading to a glioma CpG island methylator phenotype.
Year:
2025
The contribution of rare pathogenic/likely pathogenic (P/LP) germline variants to pediatric central nervous system (CNS) tumor development remains understudied. Here, we characterized the prevalence and clinical significance of germline P/LP variants in cancer predisposition genes across 830 CNS tumor patients from the Pediatric Brain Tumor Atlas (PBTA). We identified germline P/LP variants in 23.3% (193/830) of patients and the majority (137/193) lacked clinical reporting of genetic tumor syndromes. Among P/LP carriers, 34.6% had putative somatic second hits or loss of function tumor alterations. Finally, we linked pathogenic germline variation with novel somatic events and patient survival to highlight the impact of germline variation on tumorigenesis and patient outcomes.
Year:
2025
Purpose: Tropomyosin receptor kinase (TRK) fusions are detected in less than 2% of central nervous system tumors. There are limited data on the clinical course of affected patients. Experimental Design: We conducted an international retrospective cohort study of patients with TRK fusion–driven central nervous system tumors. Results: A total of 119 patients were identified. The median age at the time of diagnosis was 4.5 years. The majority were reported to have a histology consistent with a diagnosis of high-grade glioma (HGG; 57.1%) followed by low-grade glioma (LGG; 27.7%). Pediatric patients had a better prognosis, with a median overall survival of 185.5 months compared with 24.8 months in adults ( P P = 0.0012). The objective response was 68.8% with larotrectinib compared with 38.1% for nontargeted treatment. Conclusions: Children with LGG had a favorable outcome compared with adult glioma and HGG. TRK inhibitors seem to improve tumor control.
Year:
2025
Supplementary Data S1. Definition of response, Description of response criteria used by sites to evaluate tumor response, Definition of extend of resection, Definition of extend of resection used by sites.
Year:
2025
Supplementary Figure S2. A) Hazard ratio for progression or death according to clinical characteristics. B) Hazard ratio for death according to clinical characteristics. LGG: Low-grade glioma, HGG: High-grade glioma
Year:
2025
Background Central nervous system (CNS) tumors lead to cancer-related mortality in children. Genetic ancestry-associated cancer prevalence and outcomes have been studied but are limited. Methods We performed genetic ancestry prediction in 1,452 pediatric patients with paired normal and tumor whole genome sequencing from the Open Pediatric Cancer (OpenPedCan) project to evaluate the influence of reported race and ethnicity and ancestry-based genetic superpopulations on tumor histology, molecular subtype, survival, and treatment. Results Predicted superpopulations included African (AFR, N = 153), Admixed American (AMR, N = 222), East Asian (EAS, N = 67), European (EUR, N = 968), and South Asian (SAS, N = 42). Reported race and ethnicity and ancestry-based genetic superpopulations were non-randomly associated (P < .001). Patients with an atypical teratoid rhabdoid tumor or meningioma were enriched for AFR ancestry (OR = 2.6, FDR = 0.01; OR = 2.9, FDR = 0.01, respectively). Among KIAA1549::BRAF fusion-positive low-grade glioma (LGG) diagnoses, EAS and SAS patients disproportionately harbored exon 15:09 breakpoints (FDR < 0.05), and AMR patients demonstrated rare breakpoints, which were associated with lesser degree of surgical resection and worse event-free survival (EFS) versus other breakpoints (hazard ratio (HR) = 4.6, P = .03). Non-EUR and AMR patients with germ cell tumors and SHH-activated medulloblastoma, respectively, exhibited worse EFS relative to EUR patients (HR = 12.1, P < .01; HR = 5.2, P = .03) and AFR patients with LGG (HR = 16.4, P < .01) or ependymoma (HR = 5.5, P = .02) had worse overall survival compared to EUR patients. We observed a higher frequency of clinical trial enrollment among AMR patients across tumor histologies (OR = 2.0, P ≤ .01), but increased utilization of photon versus proton radiation relative to other superpopulations (OR = 0.55, P= .04). Conclusions Genetic ancestry-associated differences exist across pediatric CNS tumor histological and molecular subtypes from PBTA and PNOC. Further investigation into genetic and socioeconomic factors contributing to these observed inequities is needed.
Year:
2025
To overcome the paucity of known tumor-specific surface antigens in pediatric high-grade glioma (pHGG), we contrasted splicing patterns in pHGGs and normal brain samples. Among alternative splicing events affecting extracellular protein domains, the most pervasive alteration was the skipping of ≤30 nucleotide-long exons. Several of these skipped microexons mapped to L1-IgCAM family members, such as NRCAM . Bulk and single-nuclei short- and long-read RNA-seq revealed uniform skipping of NRCAM microexons 5 and 19 in virtually every pHGG sample. Importantly, the Δex5Δex19 (but not the full-length) NRCAM proteoform was essential for pHGG cell migration and invasion in vitro and tumor growth in vivo. We developed a monoclonal antibody selective for Δex5Δex19 NRCAM and demonstrated that “painting” of pHGG cells with this antibody enables killing by T cells armed with an FcRI-based universal immune receptor. Thus, pHGG-specific NRCAM and possibly other L1-IgCAM proteoforms are promising and highly selective targets for adoptive immunotherapies.
Year:
2025
Patients with H3K27M-mutant diffuse midline glioma (DMG) have no proven effective therapies. ONC201 has recently demonstrated efficacy in these patients, but the mechanism behind this finding remains unknown. We assessed clinical outcomes, tumor sequencing, and tissue/cerebrospinal fluid (CSF) correlate samples from patients treated in two completed multisite clinical studies. Patients treated with ONC201 following initial radiation but prior to recurrence demonstrated a median overall survival of 21.7 months, whereas those treated after recurrence had a median overall survival of 9.3 months. Radiographic response was associated with increased expression of key tricarboxylic acid cycle–related genes in baseline tumor sequencing. ONC201 treatment increased 2-hydroxyglutarate levels in cultured H3K27M-DMG cells and patient CSF samples. This corresponded with increases in repressive H3K27me3 in vitro and in human tumors accompanied by epigenetic downregulation of cell cycle regulation and neuroglial differentiation genes. Overall, ONC201 demonstrates efficacy in H3K27M-DMG by disrupting integrated metabolic and epigenetic pathways and reversing pathognomonic H3K27me3 reduction. Significance: The clinical, radiographic, and molecular analyses included in this study demonstrate the efficacy of ONC201 in H3K27M-mutant DMG and support ONC201 as the first monotherapy to improve outcomes in H3K27M-mutant DMG beyond radiation. Mechanistically, ONC201 disrupts integrated metabolic and epigenetic pathways and reverses pathognomonic H3K27me3 reduction. This article is featured in Selected Articles from This Issue, p. 2293
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Collaborators (84)
Matthew Hall
Associate Clinical Professor
Florida International University
Chandan Kumar
Associate Research Scientist
University of Michigan
Ali Nabavizadeh
University of Pennsylvania
Raja Mazumder
George Washington University
Sharon Diskin
Associate Professor
University of Pennsylvania
Mariella Spalato Ceruso
Institut Bergonié
Sebastian Waszak
Tenure Track Assistant Professor
University of California, San Francisco
Jordan R Hansford
Oncologist
University of Melbourne
Mariella Filbin
Dana-Farber Cancer Institute
Arul M Chinnaiyan
University of Michigan
Sarah Tasian
Associate Professor
University of Pennsylvania
Yoshie Umemura
Barrow Neurological Institute
Miriam Bornhorst
Ann and Robert H Lurie Children's Hospital of Chicago
Rajen J. Mody
University of Michigan
Angela Waanders
Associate Professor
Ann and Robert H Lurie Children's Hospital of Chicago
Uri Tabori
Section Head of Neuro-Oncology
Hospital for Sick Children
Frank Lin
Baylor College of Medicine Department of Pediatrics
Holly Lindsay
Associate Professor
University of Colorado Health
Ingrid Øra
MD, PhD, Assoc Prof
Lund University
minesh mehta
Chair
Florida International University
Birgit Geoerger
Université Paris-Saclay
Anna Schwendeman
-
Daniel J. Powell
Associate Professor
University of Pennsylvania
Timothy Cloughesy
Director of NeuroOncology Program/Professor
Ronald Reagan UCLA Medical Center
Jonathon Keeney
Assistant Research Professor
George Washington University
David Ziegler
Professor
University of New South Wales
Michelle M Kim
University of Michigan
Eugene Hwang
Chief
Children's National Medical Center
Hagen U Tilgner
Associate Professor
Weill Cornell Medicine
Sriram Venneti
Professor
University of Michigan
Alexander Drilon
Thomas Jefferson University Hospital
Chantel Cacciotti
Western University
Chris Jones
Professor of Childhood Brain Tumour Biology
Institute of Cancer Research
Maura Massimino
Direttore S.C
Fondazione IRCCS Istituto Nazionale dei Tumori
Kara Maxwell
Assistant Professor
University of Pennsylvania
Kathryn McFadden
Associate Clinical Professor
Izaak Walton Killam Health Centre
Aleksandar Mihajlovic
Head of Operations
APIS Assay Technologies Ltd
elisabetta schiavello
Fondazione IRCCS Istituto Nazionale dei Tumori
Lili Zhao
Professor
Northwestern University
Charles Burant
University of Michigan
Daniel Orbach
-
Sabine Mueller
Adjunt Associate Professor
University of California
Nathalie Agar
Principal Investigator
Brigham and Women's Hospital
Yoseph Barash
Proffesor
University of Pennsylvania
Christopher L Moertel
University of Minnesota
Nathan Robison
Assistant Professor of Clinical Pediatrics
University of Southern California Keck School of Medicine
Jo Lynne Rokita
Director, Brain Tumor Institute Bioinformatics Core
Children's National Health System
Deanne Taylor
Research Associate Professor
University of Pennsylvania
Nicholas Gottardo
University of Western Australia
Rajan Jain
Professor
NYU Langone Health
Rawan Hammad
Assistant professor
king abdulaziz university
John Maris
PI
University of Pennsylvania
Matthew Dun
Professor Paediatric Heamatology/Oncology Research
Hunter Medical Research Institute
Nada Jabado
Professor
McGill University
Jamie Spangler
Assistant Professor
Johns Hopkins University
Susanne Schmidt
Group Leader
University of Bonn
Mathieu Quesnel-Vallières
Assistant Professor
Université de Sherbrooke
Carl Koschmann
University of Michigan Medical School
Marilyn Li
Associate Chair and Vice Chief of Division of Genomic Diagnoatics
Children's Hospital of Philadelphia
Andrea T. Franson
-
Lenka Krsková
First Faculty of Medicine Charles University and University Hospital Motol
Javad Nazarian
Lead, DMG Research Center
-
Shankar Subramaniam
University of California, San Diego
Chan Chung
Principal investigator
Daegu Gyeongbuk Institute of Science and Technology
Theodore Laetsch
Associate Professor
Children's Hospital of Philadelphia
Michal Zapotocky
University Hospital in Motol
Benjamin M Ellingson
Professor
University of California, Los Angeles
Michael Prados
University of California
Andrei Thomas-Tikhonenko
Division Chief
Children's Hospital of Philadelphia
Audrey-Anne Lamoureux
Université de Montréal
Thomas De Raedt
Assistant Professor
Children's Hospital of Philadelphia
Donald Parsons
Professor
Baylor College of Medicine
Alexander Lachmann
Assistant Professor
Icahn School of Medicine at Mount Sinai
Alexander G. Weil
-
Alex Brown
Professor
Telethon Kids Institute
Thinh Quoc Nguyen
Thomas Jefferson University
Aleksandar Milosavljevic
Baylor College of Medicine
Kai Wang
Professor
University of Pennsylvania
Avi Ma'ayan
Professor
Icahn School of Medicine at Mount Sinai
Daniel R. Wahl
University of Michigan
Nicolas U. Gerber
University Children's Hospital Zurich
Jacques Grill
Head day care
Gustave Roussy
Costas A. Lyssiotis
University of Michigan
Sharon L Gardner
Associate Professor (Clinical) of Pediatrics
NYU School of Medicine
Make your next move.
Prepare your application
Review drafts before you send them.